key: cord-0975541-y6cau1q6
authors: Chong, Vui Heng; Chong, Pui Lin; Metussin, Dhiya; Asli, Rosmonaliza; Momin, Riamiza Natalie; Mani, Babu Ivan; Abdullah, Muhammad Syafiq
title: Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID‐19
date: 2020-05-22
journal: J Med Virol
DOI: 10.1002/jmv.26004
sha: 11d49f174f06b4d12af84a71fd89e1e81489c5eb
doc_id: 975541
cord_uid: y6cau1q6

COVID-19 is a contagious disease caused by Severe Adult Respiratory Syndrome Corona Virus-2 (SARS-CoV-2). Currently the role of HCQ in COVID-19 remains controversial but HCQ continued to be used in the absence of any effective therapy. We showed that cardiac conduction abnormalities were common in patients with HCQ added on to lopinavir/ritonavir. After starting HCQ, there were 5 (45.5%) new events of which four (36.3%) were attributed to HCQ: QTc prolongations in 3 patients with additional development of conduction blocks (fascicular block and right bundle brunch block in one patient respectively) and one patient with bradycardia. All conduction abnormalities settled after discontinuation of HCQ. Therefore monitoring is recommended when considering HCQ in treating patients with COVID-19. This article is protected by copyright. All rights reserved.

Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19

To the Editor,

We read with interest the systematic review and meta-analysis by Sarma et al 1 on the use of hydroxychloroquine (HCQ) in coronavirus disease-2019 . They concluded that more evidence is required for definitive conclusions and recommended electrocardiography (ECG) monitoring. Currently, the role of HCQ in COVID-19 remains controversial but continued to be used in the absence of effective therapy. 2, 3 We like to add on our experience with use of HCQ as add on therapy for COVID-19.

To date, we have 138 reverse transcriptase-polymerase chain reaction (RT-PCR) confirmed COVID-19 cases, of which 48 have received treatment following our treatment protocol. Mild cases were monitored and given symptomatic treatment whereas moderate/severe cases or with any of the followings; chest radiograph (CXR) changes, age more than 60 years with comorbidities (diabetes, immunocompromised, pulmonary, or cardiovascular disease), persistent fever and/or diarrhea, lymphopenia, neutrophil to lymphocyte ratio greater than or equal to 3.1 and National Early Warning Score (≥5) were started on treatment. Our treatment consist of lopinavirritonavir (400/100 mg; twice daily at least 14 days) as the first line.

HCQ (400 mg twice daily day-1 and 200 mg twice daily day-2-5) was added if there was no response to lopinavir/ritonavir. Patients also received Tamiflu (75 mg twice daily; 5 days), and antibiotics when indicated. Other medications associated with QTc prolongation (defined as > 450 ms for male and >470 ms for female) were not used. ECG were done at baseline (before the first dose of HCQ), day-2, day-4, and when indicated. Laboratory investigations were done on admission and as required. Patients were discharged after recovering with two consecutive negative RT-PCR 24 hours apart after 13 days from diagnosis.

Eleven patients had HCQ added on at a median of 2 days (range, 0-6) after starting lopinavir/ritonavir (Table 1) . Two patients (18%) had acute kidney failure (case-1 and case-10) on admission and none had any known cardiac disease. Baseline (pre-HCQ) ECGs were normal apart from two (18%) patients who had QTc prolongation. Case-4 was started on HCQ as the QTc prolongation was not critical (defined as QTc >500 ms) and in case-1 due his critical nature and disease progression despite lopinavir/ ritonavir. After starting HCQ, there were five (45.5%) new events;

prolonged QTc in three including one associated with right bundle brunch block, one with bradycardia, and one with thrombocytopenia. HCQ was discontinued in five (45.5%) patients (Table 1 ). All conduction abnormalities normalized after HCQ discontinuation. prolonged QTc interval (> 500 ms). These studies had used HCQ and azithromycin combination. Literature on HCQ use in rheumatic disorders also reported common cardiac side effects. 6 On the other hand, study has also shown HCQ and chloroquine to be associated with reduction cardiovascular risk in patients with rheumatic disorders. 7 However, this was likely due to the reduction in atherosclerosis-related events. Our patient with bradycardia was possibly related to HCQ (WHO-UMC system; possible), which resolved several days after discontinuation of HCQ, whereas the case with thrombocytopenia was not.

Most medications currently used for COVID-19 (HCQ, chloroquine, lopinavir/ritonavir, and azithromycin) are associated with QTc prolongation. Two of our patients with pre-HCQ QTc prolongation were on lopinavir/ritonavir. However, there were other factors such as acute renal failure and critical illness (case-1). Off major concern is the potential widespread use of HCQ and chloroquine due to recommendation for treatment or as prophylaxis for COVID-19. 8 As recommended by Sarma et al 1 monitoring (ECG) is essential if HCQ is to be considered. In addition, risk score should be considered. 9 HCQ is also associated with many noncardiac adverse effects (ie, metabolic such as hypo and hyperglycemia, gastrointestinal, ophthalmic, neurological, musculoskeletal, dermatological, and psychiatric). 10, 11 In the meantime, we have currently held off using HCQ for treating patients with COVID-19. 

Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review and meta-analysis

Regulators split on antimalarials for COVID-19

Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin

Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature

Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis

Development and validation of a risk score to predict QT interval prolongation in hospitalized patients

Does pandemic justify the use of hydroxychloroquine for treatment and prevention of COVID-19 in India?

Chloroquine and hydroxychloroquine for the prevention or treatment of novel coronavirus disease (COVID-19) in Africa: caution for inappropriate off-label use in healthcare settings

Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic